CDK4 and glioblastoma: Glioblastoma is one of the most aggressive cancers, although data are not yet mature, preliminary studies do not show a clear-cut benefit of immunotherapy in glioblastoma [65], while clinical studies have demonstrated that CDK4/6 inhibitor alone was not an effective treatment for recurrent glioblastoma [66,67].